Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study

Richard R. Furman, Herbert A. Eradat, Christine G. DiRienzo, Craig C. Hofmeister, Suzanne R. Hayman, John P. Leonard, Morton Coleman, Ranjana Advani, Asher A Chanan Khan, Julie Switzky, Qiming M. Liao, Damini Shah, Roxanne C. Jewell, Steen Lisby, Thomas S. Lin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background The development of more effective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenström's macroglobulinaemia. The aim of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and relapsed Waldenström's macroglobulinaemia. Methods We did a phase 2, open-label, single-arm study at six centres (hospitals and cancer clinics) in the USA. Patients aged at least 18 years who were diagnosed with untreated or relapsed Waldenström's macroglobulinaemia and required treatment, received up to three cycles of weekly ofatumumab for 5 weeks. For cycle 1, patients received one of two treatment regimens. Group A received ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2–4. Because of the acceptable safety of the 1000 mg dose in treatment group A and clinical activity of the 2000 mg dose established in chronic lymphocytic leukaemia, the study was amended on Dec 9, 2009, to change cycle 1 for group B who received ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 5–16 for treatment group A and during weeks 6–16 for treatment group B (no treatment was given during this follow-up). Patients in both groups with stable disease or a minor response after 16 weeks were eligible to then receive a redosing cycle of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 6–16 after the redosing cycle (no treatment was given during this follow-up). Patients responding to cycle 1 or the redosing cycle who developed disease progression within 36 months could receive cycle 2 of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. The primary endpoint for this study was the proportion of patients who achieved an overall response (complete responses plus partial responses plus minor responses) after each treatment cycle in the intent-to-treat population every 4 weeks starting at week 8. This trial is registered at www.ClinicalTrials.gov, NCT00811733, and is now complete. Findings Between March 17, 2009, and Feb 24, 2011, we enrolled and assigned 37 patients to treatment (15 in treatment group A and 22 in treatment group B). All 37 were included in the efficacy and safety analyses. 19 (51%, 95% CI 34·4–68·1) of 37 patients achieved an overall response after cycle 1 and 22 (59%, 42·1–75·2) of 37 achieved an overall response after the redosing cycle; 15 (41%) with partial responses, seven (19%) with minor responses. 13 patients received treatment cycle 2; ten (77%) of the 13 achieved a response. All 37 patients had at least one adverse event; 16 (43%) patients had events of grade 3 or more (30 grade 3, one grade 4). The most common grade 3 or 4 adverse events were infusion reactions (four [11%] of 37), chest pain (two [5%] of 37), haemolysis (two [5%] of 37), and neutropenia (two [5%] of 37). Two (9%) of 22 patients (both in treatment group B) had an IgM flare. 12 patients reported serious adverse events; haemolysis and pyrexia were the most common (each occurring in two [5%] of 37 patients). Interpretation A high proportion of patients achieved an overall response with ofatumumab monotherapy and this treatment was well tolerated, with a low incidence of IgM flare. This therapy might be a non-chemotherapeutic treatment option for patients with Waldenström's macroglobulinaemia, especially those with high IgM concentrations. Funding GlaxoSmithKline and Genmab.

Original languageEnglish (US)
Pages (from-to)e24-e34
JournalThe Lancet Haematology
Volume4
Issue number1
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Waldenstrom Macroglobulinemia
Therapeutics
Immunoglobulin M
ofatumumab
Hemolysis
Safety
Cancer Care Facilities

ASJC Scopus subject areas

  • Hematology

Cite this

Furman, R. R., Eradat, H. A., DiRienzo, C. G., Hofmeister, C. C., Hayman, S. R., Leonard, J. P., ... Lin, T. S. (2017). Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. The Lancet Haematology, 4(1), e24-e34. https://doi.org/10.1016/S2352-3026(16)30166-1

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia : an open-label, single-arm, phase 2 study. / Furman, Richard R.; Eradat, Herbert A.; DiRienzo, Christine G.; Hofmeister, Craig C.; Hayman, Suzanne R.; Leonard, John P.; Coleman, Morton; Advani, Ranjana; Chanan Khan, Asher A; Switzky, Julie; Liao, Qiming M.; Shah, Damini; Jewell, Roxanne C.; Lisby, Steen; Lin, Thomas S.

In: The Lancet Haematology, Vol. 4, No. 1, 01.01.2017, p. e24-e34.

Research output: Contribution to journalArticle

Furman, RR, Eradat, HA, DiRienzo, CG, Hofmeister, CC, Hayman, SR, Leonard, JP, Coleman, M, Advani, R, Chanan Khan, AA, Switzky, J, Liao, QM, Shah, D, Jewell, RC, Lisby, S & Lin, TS 2017, 'Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study', The Lancet Haematology, vol. 4, no. 1, pp. e24-e34. https://doi.org/10.1016/S2352-3026(16)30166-1
Furman, Richard R. ; Eradat, Herbert A. ; DiRienzo, Christine G. ; Hofmeister, Craig C. ; Hayman, Suzanne R. ; Leonard, John P. ; Coleman, Morton ; Advani, Ranjana ; Chanan Khan, Asher A ; Switzky, Julie ; Liao, Qiming M. ; Shah, Damini ; Jewell, Roxanne C. ; Lisby, Steen ; Lin, Thomas S. / Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia : an open-label, single-arm, phase 2 study. In: The Lancet Haematology. 2017 ; Vol. 4, No. 1. pp. e24-e34.
@article{421eb4fc3b624036956f064ba0bb7ac9,
title = "Once-weekly ofatumumab in untreated or relapsed Waldenstr{\"o}m's macroglobulinaemia: an open-label, single-arm, phase 2 study",
abstract = "Background The development of more effective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenstr{\"o}m's macroglobulinaemia. The aim of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and relapsed Waldenstr{\"o}m's macroglobulinaemia. Methods We did a phase 2, open-label, single-arm study at six centres (hospitals and cancer clinics) in the USA. Patients aged at least 18 years who were diagnosed with untreated or relapsed Waldenstr{\"o}m's macroglobulinaemia and required treatment, received up to three cycles of weekly ofatumumab for 5 weeks. For cycle 1, patients received one of two treatment regimens. Group A received ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2–4. Because of the acceptable safety of the 1000 mg dose in treatment group A and clinical activity of the 2000 mg dose established in chronic lymphocytic leukaemia, the study was amended on Dec 9, 2009, to change cycle 1 for group B who received ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 5–16 for treatment group A and during weeks 6–16 for treatment group B (no treatment was given during this follow-up). Patients in both groups with stable disease or a minor response after 16 weeks were eligible to then receive a redosing cycle of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 6–16 after the redosing cycle (no treatment was given during this follow-up). Patients responding to cycle 1 or the redosing cycle who developed disease progression within 36 months could receive cycle 2 of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. The primary endpoint for this study was the proportion of patients who achieved an overall response (complete responses plus partial responses plus minor responses) after each treatment cycle in the intent-to-treat population every 4 weeks starting at week 8. This trial is registered at www.ClinicalTrials.gov, NCT00811733, and is now complete. Findings Between March 17, 2009, and Feb 24, 2011, we enrolled and assigned 37 patients to treatment (15 in treatment group A and 22 in treatment group B). All 37 were included in the efficacy and safety analyses. 19 (51{\%}, 95{\%} CI 34·4–68·1) of 37 patients achieved an overall response after cycle 1 and 22 (59{\%}, 42·1–75·2) of 37 achieved an overall response after the redosing cycle; 15 (41{\%}) with partial responses, seven (19{\%}) with minor responses. 13 patients received treatment cycle 2; ten (77{\%}) of the 13 achieved a response. All 37 patients had at least one adverse event; 16 (43{\%}) patients had events of grade 3 or more (30 grade 3, one grade 4). The most common grade 3 or 4 adverse events were infusion reactions (four [11{\%}] of 37), chest pain (two [5{\%}] of 37), haemolysis (two [5{\%}] of 37), and neutropenia (two [5{\%}] of 37). Two (9{\%}) of 22 patients (both in treatment group B) had an IgM flare. 12 patients reported serious adverse events; haemolysis and pyrexia were the most common (each occurring in two [5{\%}] of 37 patients). Interpretation A high proportion of patients achieved an overall response with ofatumumab monotherapy and this treatment was well tolerated, with a low incidence of IgM flare. This therapy might be a non-chemotherapeutic treatment option for patients with Waldenstr{\"o}m's macroglobulinaemia, especially those with high IgM concentrations. Funding GlaxoSmithKline and Genmab.",
author = "Furman, {Richard R.} and Eradat, {Herbert A.} and DiRienzo, {Christine G.} and Hofmeister, {Craig C.} and Hayman, {Suzanne R.} and Leonard, {John P.} and Morton Coleman and Ranjana Advani and {Chanan Khan}, {Asher A} and Julie Switzky and Liao, {Qiming M.} and Damini Shah and Jewell, {Roxanne C.} and Steen Lisby and Lin, {Thomas S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/S2352-3026(16)30166-1",
language = "English (US)",
volume = "4",
pages = "e24--e34",
journal = "The Lancet Haematology",
issn = "2352-3026",
publisher = "Lancet Publishing Group",
number = "1",

}

TY - JOUR

T1 - Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia

T2 - an open-label, single-arm, phase 2 study

AU - Furman, Richard R.

AU - Eradat, Herbert A.

AU - DiRienzo, Christine G.

AU - Hofmeister, Craig C.

AU - Hayman, Suzanne R.

AU - Leonard, John P.

AU - Coleman, Morton

AU - Advani, Ranjana

AU - Chanan Khan, Asher A

AU - Switzky, Julie

AU - Liao, Qiming M.

AU - Shah, Damini

AU - Jewell, Roxanne C.

AU - Lisby, Steen

AU - Lin, Thomas S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background The development of more effective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenström's macroglobulinaemia. The aim of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and relapsed Waldenström's macroglobulinaemia. Methods We did a phase 2, open-label, single-arm study at six centres (hospitals and cancer clinics) in the USA. Patients aged at least 18 years who were diagnosed with untreated or relapsed Waldenström's macroglobulinaemia and required treatment, received up to three cycles of weekly ofatumumab for 5 weeks. For cycle 1, patients received one of two treatment regimens. Group A received ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2–4. Because of the acceptable safety of the 1000 mg dose in treatment group A and clinical activity of the 2000 mg dose established in chronic lymphocytic leukaemia, the study was amended on Dec 9, 2009, to change cycle 1 for group B who received ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 5–16 for treatment group A and during weeks 6–16 for treatment group B (no treatment was given during this follow-up). Patients in both groups with stable disease or a minor response after 16 weeks were eligible to then receive a redosing cycle of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 6–16 after the redosing cycle (no treatment was given during this follow-up). Patients responding to cycle 1 or the redosing cycle who developed disease progression within 36 months could receive cycle 2 of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. The primary endpoint for this study was the proportion of patients who achieved an overall response (complete responses plus partial responses plus minor responses) after each treatment cycle in the intent-to-treat population every 4 weeks starting at week 8. This trial is registered at www.ClinicalTrials.gov, NCT00811733, and is now complete. Findings Between March 17, 2009, and Feb 24, 2011, we enrolled and assigned 37 patients to treatment (15 in treatment group A and 22 in treatment group B). All 37 were included in the efficacy and safety analyses. 19 (51%, 95% CI 34·4–68·1) of 37 patients achieved an overall response after cycle 1 and 22 (59%, 42·1–75·2) of 37 achieved an overall response after the redosing cycle; 15 (41%) with partial responses, seven (19%) with minor responses. 13 patients received treatment cycle 2; ten (77%) of the 13 achieved a response. All 37 patients had at least one adverse event; 16 (43%) patients had events of grade 3 or more (30 grade 3, one grade 4). The most common grade 3 or 4 adverse events were infusion reactions (four [11%] of 37), chest pain (two [5%] of 37), haemolysis (two [5%] of 37), and neutropenia (two [5%] of 37). Two (9%) of 22 patients (both in treatment group B) had an IgM flare. 12 patients reported serious adverse events; haemolysis and pyrexia were the most common (each occurring in two [5%] of 37 patients). Interpretation A high proportion of patients achieved an overall response with ofatumumab monotherapy and this treatment was well tolerated, with a low incidence of IgM flare. This therapy might be a non-chemotherapeutic treatment option for patients with Waldenström's macroglobulinaemia, especially those with high IgM concentrations. Funding GlaxoSmithKline and Genmab.

AB - Background The development of more effective and safer treatments, especially non-chemotherapeutics, is needed for patients with Waldenström's macroglobulinaemia. The aim of the study was to assess the safety and clinical activity of intravenous ofatumumab monotherapy for untreated and relapsed Waldenström's macroglobulinaemia. Methods We did a phase 2, open-label, single-arm study at six centres (hospitals and cancer clinics) in the USA. Patients aged at least 18 years who were diagnosed with untreated or relapsed Waldenström's macroglobulinaemia and required treatment, received up to three cycles of weekly ofatumumab for 5 weeks. For cycle 1, patients received one of two treatment regimens. Group A received ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2–4. Because of the acceptable safety of the 1000 mg dose in treatment group A and clinical activity of the 2000 mg dose established in chronic lymphocytic leukaemia, the study was amended on Dec 9, 2009, to change cycle 1 for group B who received ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 5–16 for treatment group A and during weeks 6–16 for treatment group B (no treatment was given during this follow-up). Patients in both groups with stable disease or a minor response after 16 weeks were eligible to then receive a redosing cycle of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. We followed up patients during weeks 6–16 after the redosing cycle (no treatment was given during this follow-up). Patients responding to cycle 1 or the redosing cycle who developed disease progression within 36 months could receive cycle 2 of ofatumumab 300 mg during week 1 and 2000 mg during weeks 2–5. The primary endpoint for this study was the proportion of patients who achieved an overall response (complete responses plus partial responses plus minor responses) after each treatment cycle in the intent-to-treat population every 4 weeks starting at week 8. This trial is registered at www.ClinicalTrials.gov, NCT00811733, and is now complete. Findings Between March 17, 2009, and Feb 24, 2011, we enrolled and assigned 37 patients to treatment (15 in treatment group A and 22 in treatment group B). All 37 were included in the efficacy and safety analyses. 19 (51%, 95% CI 34·4–68·1) of 37 patients achieved an overall response after cycle 1 and 22 (59%, 42·1–75·2) of 37 achieved an overall response after the redosing cycle; 15 (41%) with partial responses, seven (19%) with minor responses. 13 patients received treatment cycle 2; ten (77%) of the 13 achieved a response. All 37 patients had at least one adverse event; 16 (43%) patients had events of grade 3 or more (30 grade 3, one grade 4). The most common grade 3 or 4 adverse events were infusion reactions (four [11%] of 37), chest pain (two [5%] of 37), haemolysis (two [5%] of 37), and neutropenia (two [5%] of 37). Two (9%) of 22 patients (both in treatment group B) had an IgM flare. 12 patients reported serious adverse events; haemolysis and pyrexia were the most common (each occurring in two [5%] of 37 patients). Interpretation A high proportion of patients achieved an overall response with ofatumumab monotherapy and this treatment was well tolerated, with a low incidence of IgM flare. This therapy might be a non-chemotherapeutic treatment option for patients with Waldenström's macroglobulinaemia, especially those with high IgM concentrations. Funding GlaxoSmithKline and Genmab.

UR - http://www.scopus.com/inward/record.url?scp=85007342198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007342198&partnerID=8YFLogxK

U2 - 10.1016/S2352-3026(16)30166-1

DO - 10.1016/S2352-3026(16)30166-1

M3 - Article

C2 - 27914971

AN - SCOPUS:85007342198

VL - 4

SP - e24-e34

JO - The Lancet Haematology

JF - The Lancet Haematology

SN - 2352-3026

IS - 1

ER -